Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
In many of the first treatment trials with tacrine, heterogeneity in treatment response was observed and discussed. One third of the patients were considered to be responders to treatment, one third unchanged and one third non-responders. Factors outlined as possible positive predictors of treatment were among others old age, well preserved frontal lobes, and presence of the APOE e4 allele. Unfort